Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Investigations prospectively collected the SCLC patients who received current standard
first-line treatment, the response was not progression disease(PD). and then participants
receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented
PD or had unacceptable toxicity. This regimen is compared to the effects a observation
without treatment after the first-line therapy. The aim of the study is therefore to evaluate
the efficacy and safety of Anlotinib as maintenance treatment after first-line chemotherapy
in SCLC patients.